⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574019 | 1.00 | NFE2L2 (0.65) | — | |
| SCHEMBL18472616 | 1.00 | — | — | |
| SCHEMBL24197 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL29768617 | 0.98 | NFE2L2 (0.62) | — | |
| Ammonia Solution, Strong SCHEMBL27509053 | 0.98 | NFE2L2 (0.62) | — | |
| Hydrochloric Acid SCHEMBL29084496 | 0.98 | NFE2L2 (0.62) | — | |
| Cyclohexane SCHEMBL268585 | 0.93 | NFE2L2 (0.58) | — | |
| SCHEMBL17686281 | 0.91 | NFE2L2 (0.64) | — | |
| SCHEMBL3819301 | 0.87 | TRIM24 (0.53) | — | |
| Diethylamine SCHEMBL9301198 | 0.86 | NFE2L2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667056-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250368625-A1 | PIPERAZINES | Grünenthal GmbH (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-4626891-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | Omeros Corporation (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4618985-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | Universitat De Barcelona (ES) | 2025-09-24 | — | — | EP | disclosed |
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025122845-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | GENEP INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-12319664-B2 | Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2025-06-03 | — | — | US | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-12122764-B2 | IKAROS zinc finger family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4126848-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-3743411-B1 | HERBICIDAL 3-PHENYLISOXAZOLIN-5-CARBOXAMIDES OF CYCLOPENTENYL CARBOXYLIC ACID DERIVATIVES | BAYER AG (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022229405-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-11-03 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220306591-A1 | HERBICIDALLY ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES OF CYCLOPENTENYLCARBOXYLIC ACID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-29 | — | — | US | disclosed |
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
| WO-2022174062-A1 | METHODS AND COMPOSITIONS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-4038052-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-08-10 | — | — | EP | disclosed |
| US-20220227786-A1 | Spiro Bicyclic Inhibitors Of Menin-MLL Interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-21 | — | — | US | disclosed |
| WO-2022019892-A1 | THERAPEUTIC AGENTS AND USES THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2022-01-27 | — | — | WO | disclosed |